When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.

Ron Najafi has lived that reality firsthand. As founder of NovaBay Pharmaceuticals and Emery Pharma, he spent decades building companies at the intersection of analytical chemistry and drug development. His investigation into nitrosamine contamination in ranitidine — which led the FDA to formally validate Emery Pharma's findings — remains one of the most consequential episodes in recent pharmaceutical quality history.

In Part 1, Ron traces the scientific and entrepreneurial path that led him there, and shares what CMC teams working in drug development need to understand about impurity risk before it becomes a regulatory crisis.

Episode highlights:

• Early academic experiences and inspirations that Ron Najafi to a science career (05:46)
• Challenges and milestones in building companies like CP Lab Safety and NovaBay Pharmaceuticals (07:59)
• The invention and impact of the ECO Funnel® on lab safety and environmental responsibility (12:01)
• The formation of Emery Pharma following industry setbacks and lessons in adaptation (17:03)
• The fundamentals of impurity risk analysis, especially nitrosamine contamination in pharmaceuticals (20:56)
• The ranitidine (Zantac) NDMA discovery, its investigation, and consequences for drug regulation (23:33)
• Common sources of nitrosamine and practical advice for bioprocess risk management (27:51)
• Differences in impurity risk between small molecule and biologic drug processes (28:03)
• The necessity and regulatory expectation of impurity and leachable/extractable analysis (30:07)

Smart insight:

One of Ron's clients conducted a superficial nitrosamine risk assessment, proceeded to manufacturing, and spent approximately $6 million producing three batches. At final FDA-required testing, NDMA came back at 11,000 nanograms per pill against an acceptable daily intake limit of 96 nanograms. The batches were unusable.

A thorough risk assessment run earlier would have cost a fraction of that. If you are developing a drug with secondary or tertiary amines in your process and have not yet conducted a formal nitrosamine risk assessment, that is the one action to take after listening to this episode.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

• Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
• Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
• Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
• Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
• Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
• Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Support the show